OncoDetect AI

OncoDetect AI represents the 2026 state-of-the-art in clinical oncology platforms, utilizing a proprietary multimodal transformer architecture to synthesize disparate data streams including Whole Slide Images (WSI), DICOM radiology scans, and NGS (Next-Generation Sequencing) genomic data. Unlike first-generation diagnostic aids, OncoDetect AI employs Large Multimodal Models (LMMs) to provide not just detection, but prognostic forecasting and treatment response simulations. The platform is designed for enterprise hospital systems and specialized diagnostic labs, offering a seamless 'Single Pane of Glass' interface for oncologists. By 2026, its market position is defined by its FDA Class II and CE-MDR certifications, focusing on the reduction of false negatives in early-stage solid tumor screening. The technical infrastructure is built on a decentralized federated learning model, allowing for continuous algorithm refinement across global sites while maintaining strict patient data sovereignty. It integrates directly with major Electronic Health Records (EHR) via FHIR R4/R5 standards, automating the extraction of phenotypic data to refine its predictive accuracy beyond 96.4% across major cancer types.